Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Viral hepatitis

Page Path

HOME
TOPICS
Viral hepatitis

Review

Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee

Clin Mol Hepatol. 2020;26(4):411-429. Published online August 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0049

View: 14420 Download: 1,426 Web of Science: 63 Crossref: 64

Letter to the Editor

How does low-level viremia affect the prognosis of patients with chronic hepatitis B?

Hye Won Lee, Beom Kyung Kim

Clin Mol Hepatol. 2020;26(3):376-377. Published online June 11, 2020

DOI: https://doi.org/10.3350/cmh.2020.0121

View: 4107 Download: 117 Web of Science: 1 Crossref: 1

Original Article

Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir

Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2020;26(3):364-375. Published online May 29, 2020

DOI: https://doi.org/10.3350/cmh.2020.0012

View: 5768 Download: 265 Web of Science: 24 Crossref: 21

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn

Clin Mol Hepatol. 2020;26(3):352-363. Published online May 28, 2020

DOI: https://doi.org/10.3350/cmh.2019.0044n

View: 4769 Download: 181 Web of Science: 3 Crossref: 4

Editorial

Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?

Jung Hee Kim, Dong Hyun Sinn

Clin Mol Hepatol. 2020;26(3):315-317. Published online June 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0084

View: 4565 Download: 103 Crossref: 1

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Byoung Kuk Jang

Clin Mol Hepatol. 2020;26(3):312-314. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0099

View: 4871 Download: 119 Crossref: 2

Review

Novel biomarkers for the management of chronic hepatitis B

Takako Inoue, Yasuhito Tanaka

Clin Mol Hepatol. 2020;26(3):261-279. Published online June 15, 2020

DOI: https://doi.org/10.3350/cmh.2020.0032

View: 14629 Download: 694 Web of Science: 70 Crossref: 73

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2020;26(3):251-260. Published online March 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0018

View: 14352 Download: 387 Web of Science: 38 Crossref: 41

Letter to the Editor

A challenge in distinguishing between acute hepatitis B and acute exacerbation of chronic hepatitis B

Yang-Hyun Baek

Clin Mol Hepatol. 2020;26(2):233-235. Published online April 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0039

View: 4324 Download: 143

Original Article

The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: Is quantitative serology the answer?

Sujata Lall, Pragya Agarwala, Guresh Kumar, Manoj Kumar Sharma, Ekta Gupta

Clin Mol Hepatol. 2020;26(2):187-195. Published online April 7, 2020

DOI: https://doi.org/10.3350/cmh.2019.0060

View: 10423 Download: 336 Web of Science: 12 Crossref: 12

Editorial

Should physicians go out of the way to differentiate between acute hepatitis B and acute exacerbation of chronic hepatitis B?

Hyun Woong Lee

Clin Mol Hepatol. 2020;26(2):180-182. Published online April 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0045

View: 4018 Download: 105

Original Article

Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients

Waleed Seif Eldin Mohamed Mostafa, Mohammed Hassan Saiem Al-Dahr, Dalia Abdel Hamid Omran, Zeinab Fathy Abdullah, Suzan Hamdy Elmasry, Mohamed Nabil Ibrahim

Clin Mol Hepatol. 2020;26(1):60-69. Published online October 22, 2019

DOI: https://doi.org/10.3350/cmh.2019.0051

View: 6047 Download: 133 Web of Science: 4 Crossref: 4

Review

Extrahepatic manifestations of hepatitis E virus: An overview

Fotios S. Fousekis, Ioannis V. Mitselos, Dimitrios K. Christodoulou

Clin Mol Hepatol. 2020;26(1):16-23. Published online October 11, 2019

DOI: https://doi.org/10.3350/cmh.2019.0082

View: 9128 Download: 386 Web of Science: 34 Crossref: 34

Original Article

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection

Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang

Clin Mol Hepatol. 2019;25(4):400-407. Published online May 28, 2019

DOI: https://doi.org/10.3350/cmh.2019.0006

View: 6074 Download: 125 Web of Science: 9 Crossref: 7

Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand

Ratchapong Laiwatthanapaisan, Pimsiri Sripongpun, Naichaya Chamroonkul, Arunee Dechaphunkul, Chirawadee Sathitruangsak, Siwat Sakdejayont, Chanon Kongkamol, Teerha Piratvisuth

Clin Mol Hepatol. 2019;25(4):366-373. Published online July 17, 2019

DOI: https://doi.org/10.3350/cmh.2018.0111

View: 5104 Download: 107 Web of Science: 3 Crossref: 5

Review

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

Tommaso Lorenzo Parigi, Maria Corina Plaz Torres, Alessio Aghemo

Clin Mol Hepatol. 2019;25(4):360-365. Published online May 2, 2019

DOI: https://doi.org/10.3350/cmh.2019.0022

View: 5436 Download: 242 Web of Science: 9 Crossref: 10

Letter to the editor

Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report

Rahul Kumar, John Chen Hsiang, Jessica Tan, Prem Harichander Thurairajah

Clin Mol Hepatol. 2019;25(3):326-330. Published online December 4, 2018

DOI: https://doi.org/10.3350/cmh.2018.0063

View: 11193 Download: 101 Web of Science: 2 Crossref: 3

Original Article

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol. 2019;25(3):283-293. Published online November 13, 2018

DOI: https://doi.org/10.3350/cmh.2018.0054

View: 9917 Download: 241 Web of Science: 29 Crossref: 33

Editorial

How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?

Jung Hwan Yu, Jin-Woo Lee

Clin Mol Hepatol. 2019;25(3):280-282. Published online January 21, 2019

DOI: https://doi.org/10.3350/cmh.2018.0104

View: 5408 Download: 124 Web of Science: 1 Crossref: 1

Review

Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C

Seong Kyun Na, Byung-Cheol Song

Clin Mol Hepatol. 2019;25(3):234-244. Published online January 21, 2019

DOI: https://doi.org/10.3350/cmh.2018.0108

View: 8030 Download: 245 Web of Science: 21 Crossref: 23

Original Article

Are there differences in risk factors, microbial aspects, and prognosis of cellulitis between compensated and decompensated hepatitis C virus-related cirrhosis?

Elham Ahmed Hassan, Abeer Sharaf El-Din Abdel Rehim, Mohamed Omar Abdel-Malek, Asmaa Omar Ahmed, Nourhan Mahmoud Abbas

Clin Mol Hepatol. 2019;25(3):317-325. Published online June 10, 2019

DOI: https://doi.org/10.3350/cmh.2018.0097

View: 9519 Download: 121 Web of Science: 2 Crossref: 1

Letter to the editor

VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature

Yu Jun Wong, Si Yuan Chew, John Chen Hsiang, Prem Harichander Thurairajah, Rahul Kumar, Eng Kiong Teo, Roshni Sadashiv Gokhale, Imran Bin Mohamed Noor, Jessica Tan

Clin Mol Hepatol. 2019;25(2):218-222. Published online September 6, 2018

DOI: https://doi.org/10.3350/cmh.2018.0017

View: 10764 Download: 118 Web of Science: 1 Crossref: 2

Review

Unmet need in chronic hepatitis B management

Lilian Yan Liang, Grace Lai-Hung Wong

Clin Mol Hepatol. 2019;25(2):172-180. Published online February 12, 2019

DOI: https://doi.org/10.3350/cmh.2018.0106

View: 9315 Download: 394 Web of Science: 43 Crossref: 45

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2019;25(2):93-159. Published online June 12, 2019

DOI: https://doi.org/10.3350/cmh.2019.1002

View: 24403 Download: 645 Web of Science: 163 Crossref: 148

Original Article

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

Shinya Sato, Kei Moriya, Masanori Furukawa, Soichiro Saikawa, Tadashi Namisaki, Mitsuteru Kitade, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Naotaka Shimozato, Yasuhiko Sawada, Kenichiro Seki, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Yasushi Okura, Junichi Yamao, Hitoshi Yoshiji

Clin Mol Hepatol. 2019;25(1):65-73. Published online February 25, 2019

DOI: https://doi.org/10.3350/cmh.2018.0070

View: 8316 Download: 133 Web of Science: 5 Crossref: 4

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kwang-il Kim, Soo-Hwan Kim, Kyu Sung Rim, Seong Gyu Hwang

Clin Mol Hepatol. 2019;25(1):52-64. Published online October 23, 2018

DOI: https://doi.org/10.3350/cmh.2018.0040

View: 8388 Download: 338 Web of Science: 73 Crossref: 70

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia Dietz, Martin Eisenacher, Helmut E. Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph Sarrazin, Grith Lykke Sorensen, Barbara Sitek, Thilo Bracht

Clin Mol Hepatol. 2019;25(1):42-51. Published online November 19, 2018

DOI: https://doi.org/10.3350/cmh.2018.0029

View: 10212 Download: 120 Web of Science: 13 Crossref: 13

Editorial

Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.

Won Kim

Clin Mol Hepatol. 2019;25(1):40-41. Published online December 28, 2018

DOI: https://doi.org/10.3350/cmh.2018.0101

View: 6550 Download: 103 Web of Science: 1 Crossref: 1

Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C

Young Woo Eom, Soon Koo Baik

Clin Mol Hepatol. 2019;25(1):37-39. Published online December 11, 2018

DOI: https://doi.org/10.3350/cmh.2018.1011

View: 7040 Download: 100 Web of Science: 2 Crossref: 2

Review

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti

Clin Mol Hepatol. 2019;25(1):30-36. Published online January 23, 2019

DOI: https://doi.org/10.3350/cmh.2018.0061

View: 7599 Download: 152 Web of Science: 14 Crossref: 16

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

8.9
First decision

09 Days

Publication after acceptance

04 Days

*Last 12 months

Viewed By 5352	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5300	MAFLD: How is it different from NAFLD?
Viewed By 5201	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3889	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3848	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?